Last reviewed · How we verify

BG00010 — Competitive Intelligence Brief

BG00010 (BG00010) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amyloid beta antibody. Area: Neurology.

phase 2 Amyloid beta antibody Amyloid beta Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BG00010 (BG00010) — Biogen. BG00010 is a monoclonal antibody targeting amyloid beta.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BG00010 TARGET BG00010 Biogen phase 2 Amyloid beta antibody Amyloid beta
Leqembi LECANEMAB Eisai marketed Amyloid Beta-directed Antibody [EPC] Amyloid beta A4 protein 2023-01-01
Aduhelm ADUCANUMAB Biogen marketed Amyloid Beta-directed Antibody Amyloid beta A4 protein 2021-01-01
Neuraceq FLORBETABEN F18 Piramal Imaging marketed Radioactive Diagnostic Agent [EPC] Amyloid beta A4 protein 2014-01-01
Vizamyl Flutemetamol (18F) GE HealthCare marketed Radioactive Diagnostic Agent [EPC] Amyloid beta A4 protein 2013-01-01
Amyvid FLORBETAPIR F 18 Avid Radiopharms Inc marketed Radioactive Diagnostic Agent [EPC] Amyloid beta A4 protein 2012-01-01
M.V.I. Pediatric RETINOL Pfizer marketed Vitamin A Amyloid beta A4 protein 1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Amyloid beta antibody class)

  1. Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BG00010 — Competitive Intelligence Brief. https://druglandscape.com/ci/bg00010. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: